These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24522033)

  • 1. Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
    Taneja SS
    J Urol; 2014 Mar; 191(3):656. PubMed ID: 24522033
    [No Abstract]   [Full Text] [Related]  

  • 2. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
    Quinn DI; Tangen CM; Hussain M; Lara PN; Goldkorn A; Moinpour CM; Garzotto MG; Mack PC; Carducci MA; Monk JP; Twardowski PW; Van Veldhuizen PJ; Agarwal N; Higano CS; Vogelzang NJ; Thompson IM
    Lancet Oncol; 2013 Aug; 14(9):893-900. PubMed ID: 23871417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer.
    Şendur MA; Akıncı MB; Ozdemir NY; Aksoy S; Dede DS; Ulas A; Zengin N; Yalçın B
    Future Oncol; 2015; 11(8):1141-3. PubMed ID: 25832870
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
    Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
    James ND; Caty A; Payne H; Borre M; Zonnenberg BA; Beuzeboc P; McIntosh S; Morris T; Phung D; Dawson NA
    BJU Int; 2010 Oct; 106(7):966-73. PubMed ID: 20840318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
    Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
    J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
    Lara PN; Ely B; Quinn DI; Mack PC; Tangen C; Gertz E; Twardowski PW; Goldkorn A; Hussain M; Vogelzang NJ; Thompson IM; Van Loan MD
    J Natl Cancer Inst; 2014 Apr; 106(4):dju013. PubMed ID: 24565955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Docetaxel--standard therapy further optimized].
    Krankenpfl J; 2005; 43(4-6):141. PubMed ID: 16171083
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.
    Sonpavde G; Pond GR; Plets M; Tangen CM; Hussain MHA; Lara PN; Goldkorn A; Garzotto MG; Mack PC; Higano CS; Vogelzang NJ; Thompson IM; Twardowski PW; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Quinn DI
    Clin Genitourin Cancer; 2017 Dec; 15(6):635-641. PubMed ID: 28579151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
    Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.
    Boccardo F; Rubagotti A; Conti G; Battaglia M; Cruciani G; Manganelli A; Ricci S; Lapini A
    Oncology; 2008; 74(3-4):223-8. PubMed ID: 18714171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrasentan for metastatic hormone refractory prostate cancer.
    Murphy G
    Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
    Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
    Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in hormone-refractory prostate cancer.
    de Wit R
    BJU Int; 2008 Mar; 101 Suppl 2():11-5. PubMed ID: 18307687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy for hormone-refractory prostate cancer].
    Nishimura K; Takahara S; Nonomura N; Okuyama A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():266-71. PubMed ID: 12599583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.